Abstract
Background: It has been reported that administration of low‐dose aspirin significantly reduces the frequency of major cardiovascular events in patients with hypertension and coronary artery disease. It is generally considered that the preventative effects of long‐term aspirin administration on major cardiovascular events are due to the inhibition of platelet aggregation.
Hypothesis: It is not known whether administration of low‐dose aspirin restores endothelium‐dependent vasodilatation, and this study was undertaken to prove or disprove this question in patients with hypertension.
Methods: Flow‐mediated endothelium‐dependent dilatation and glyceryl trinitrate‐induced endothelium‐independent dilatation were investigated in 18 hypertensive patients and 10 normotensive control subjects. In the hypertensive patients, flow‐mediated dilatation was investigated and cyclic guano‐sine monophosphate plasma (cGMP) was measured before and at 8 weeks after the administration of 162 mg of aspirin.
Results: Flow‐mediated dilatation before aspirin administration was more reduced in the hypertensive patients than in the control subjects (6.4 ± 2.0% vs. 11.3 ± 2.3%, p< 0.0001). Glyceryl trinitrate‐induced dilatation before aspirin administration was similar in hypertensive patients and control subjects. Flow‐mediated dilatation after aspirin administration was improved compared with that before aspirin administration (10.4 ± 3.5% vs. 6.4 ± 2.0%, p<0.0004). The cGMP product after aspirin administration was significantly higher than that before aspirin administration.
Conclusions: Administration of low‐dose aspirin may restore the endothelium‐dependent vasodilatation in hypertensive patients. Furthermore, increased nitric oxide production may play a partial role in the improvement in endothelial function induced by administration of low‐dose aspirin.
Keywords: endothelial function, hypertension, aspirin, nitric oxide, cyclic guanosine monophosphate plasma
Full Text
The Full Text of this article is available as a PDF (553.5 KB).
References
- 1. Panza JA, Quyyumi AA, Brush JE, Epstein SE: Abnormal endothelium‐dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22–27 [DOI] [PubMed] [Google Scholar]
- 2. Linder L, Kiowski W, Buhler FR, Luscher TF: Indirect evidence for release of endothelium‐derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990; 81: 1762–1767 [DOI] [PubMed] [Google Scholar]
- 3. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE: Endothelium‐dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994; 24: 1468–1474 [DOI] [PubMed] [Google Scholar]
- 4. Antony I, Lerebours G, Nitenberg A: Loss of flow‐dependent coronary artery dilatation in patients with hypertension. Circulation 1995; 91: 1624–1628 [DOI] [PubMed] [Google Scholar]
- 5. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A: Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 1997; 29: 274–279 [DOI] [PubMed] [Google Scholar]
- 6. Husain S, Andrews NR Mulcahy D, Panza JA, Quyyumi AA: Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998; 97: 716–720 [DOI] [PubMed] [Google Scholar]
- 7. Becker RC: Antiplatelet therapy in coronary heart disease: Emerging strategies for the treatment and prevention of acute myocardial infarction. Arch Pathol Lab Med 1993; 117: 89–96 [PubMed] [Google Scholar]
- 8. Juul‐Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R: Double‐blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris: The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340: 1421–1425 [DOI] [PubMed] [Google Scholar]
- 9. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood‐pressure lowering and low‐dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–1762 [DOI] [PubMed] [Google Scholar]
- 10. Celermajer DS, Sorensen KE, Gooch VM, Spoegelhalter DJ, Miller OI, Sullivan I, Lloyd JK, Deanfield JE: Non‐invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111–1115 [DOI] [PubMed] [Google Scholar]
- 11. Hausleiter J, Jost S, Nolte CWT, Dirschinger J, Kastrati A, Stiel GM, Wunderlich W, Fischer F, Linderer T, Hausmann D, Schomig A: Comparative in‐vitro validation of eight first‐ and second‐generation quantitative coronary angiography systems. Coron Artery Dis 1997; 8: 83–90 [DOI] [PubMed] [Google Scholar]
- 12. Busse R, Fleming I: Endothelial dysfunction in atherosclerosis. J Vasc Res 1996; 33: 181–194 [DOI] [PubMed] [Google Scholar]
- 13. Shimokawa H, Vanhoutte PM: Endothelium and vascular injury in hypertension and atherosclerosis In Handbook of Hypertension (Eds. Zanchetti A, Marcia G.), p. 1001–1065. New York: Elsevier Science, 1997. [Google Scholar]
- 14. Harrison DG: Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 2153–2157 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Shimokawa H: Primary endothelial dysfunction: Atherosclerosis. J Moll Cell Cardiol 1999; 31: 23–37 [DOI] [PubMed] [Google Scholar]
- 16. Noon JP, Walker BR, Hand MF, Webb DJ: Impairment of forearm vasodilatation to acetylcholine in hypercholesterolemia is reversed by aspirin. Cardiovasc Res 1998; 38: 480–484 [DOI] [PubMed] [Google Scholar]
- 17. Imaizumi T, Yoshida M, Hirooka Y: Defective endothelium‐dependent vasodilation in patients with essential hypertension In Recent Progress in Cardiovascular Mechanics (Ed. Hosoda S.), p. 333–348. Switzerland: Harwood Academic Publishers, 1994. [Google Scholar]